Influence of pre-existing inflammation on the outcome of acute coronary syndrome:a cross-sectional study by Odeberg, J. et al.
Syddansk Universitet
Influence of pre-existing inflammation on the outcome of acute coronary syndrome
Odeberg, J.; Freitag, M.; Forssell, Henrik; Vaara, Ivar; Persson, Marie-Louise; Odeberg, H.;
Halling, Anders; Rastam, L.; Lindblad, Ulf
Published in:
BMJ Open
DOI:
10.1136/bmjopen-2015-009968
Publication date:
2016
Document version
Final published version
Document license
CC BY
Citation for pulished version (APA):
Odeberg, J., Freitag, M., Forssell, H., Vaara, I., Persson, M-L., Odeberg, H., ... Lindblad, U. (2016). Influence of
pre-existing inflammation on the outcome of acute coronary syndrome: a cross-sectional study. BMJ Open, 6(1),
[e009968]. DOI: 10.1136/bmjopen-2015-009968
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 19. Apr. 2017
Inﬂuence of pre-existing inﬂammation
on the outcome of acute coronary
syndrome: a cross-sectional study
Jacob Odeberg,1,2 Michael Freitag,3 Henrik Forssell,4 Ivar Vaara,5
Marie-Louise Persson,5 Håkan Odeberg,4 Anders Halling,6 Lennart Råstam,7
Ulf Lindblad8
To cite: Odeberg J,
Freitag M, Forssell H, et al.
Influence of pre-existing
inflammation on the outcome
of acute coronary syndrome:
a cross-sectional study. BMJ
Open 2016;5:e009968.
doi:10.1136/bmjopen-2015-
009968
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2015-009968).
Received 11 September 2015
Revised 24 November 2015
Accepted 25 November 2015
For numbered affiliations see
end of article.
Correspondence to
Dr Jacob Odeberg; jacob.
odeberg@scilifelab.se
ABSTRACT
Objectives: Inflammation is a well-established risk
factor for the development of coronary artery disease
(CAD) and acute coronary syndrome (ACS). However,
less is known about its influence on the outcome of
ACS. The aim of this study was to determine if blood
biomarkers of inflammation were associated
specifically with acute myocardial infarction (MI) or
unstable angina (UA) in patients with ACS.
Design: Cross-sectional study.
Setting: Patients admitted to the coronary care unit,
via the emergency room, at a central county hospital
over a 4-year period (1992–1996).
Participants: In a substudy of Carlscrona Heart Attack
Prognosis Study (CHAPS) of 5292 patients admitted to
the coronary care unit, we identified 908 patients aged
30–74 years, who at discharge had received the
diagnosis of either MI (527) or UA (381).
Main outcome measures: MI or UA, based on the
diagnosis set at discharge from hospital.
Results: When adjusted for smoking, age, sex and
duration of chest pain, concentrations of plasma
biomarkers of inflammation (high-sensitivity C reactive
protein>2 mg/L (OR=1.40 (1.00 to 1.96) and fibrinogen
(p for trend=0.035)) analysed at admission were found
to be associated with MI over UA, in an event of ACS.
A strong significant association with MI over UA was
found for blood cell markers of inflammation, that is,
counts of neutrophils (p for trend<0.001), monocytes
(p for trend<0.001) and thrombocytes (p for
trend=0.021), while lymphocyte count showed no
association. Interestingly, eosinophil count (p for
trend=0.003) was found to be significantly lower in
patients with MI compared to those with UA.
Conclusions: Our results show that, in patients with
ACS, the blood cell profile and degree of inflammation
at admission was associated with the outcome.
Furthermore, our data suggest that a pre-existing
low-grade inflammation may dispose towards MI
over UA.
INTRODUCTION
Acute coronary syndrome (ACS) is usually
initiated by an atherosclerotic plaque rupture
or disruption of the overlying endothelial
surface. Subsequent thrombosis formation
can permanently occlude the lumen of a cor-
onary artery, causing myocardial cell death
and the induction of myocardial infarction
(MI). However, in other cases, it can be tran-
sient, or only partially occlude the vessel,
resulting in unstable angina (UA).1 2 It is not
known why some patients progress to the
former, rather than the latter, outcome. It is
well established that low-grade inﬂammation
has a major pathogenic role for the progres-
sion of atherosclerotic coronary artery
lesions.1 2 A role for inﬂammatory mediators
during the evolution of ACS is indicated by
the widespread coronary inﬂammation
found during UA, throughout the entire cor-
onary artery bed, and not only in the artery
containing the culprit lesion.3 4 To what
extent ACS outcome is related to a concur-
rent inﬂammatory response or to the
degree of pre-existing inﬂammation is less
established.2 5
Strengths and limitations of this study
▪ The patients were recruited before the introduc-
tion of percutaneous coronary intervention, cor-
onary artery bypass graft and modern
antithrombotic drugs in the standard manage-
ment of acute coronary syndrome (ACS). Thus, it
was possible to identify progression to unstable
angina (UA) or myocardial infarction (MI) as dis-
tinct outcome groups within the cohort, in the
absence of interventions that would otherwise
influence the thrombotic processes involved in
ACS.
▪ The study was based in a single centre with the
same two cardiologists evaluating and categoris-
ing all 5292 patients, using consistent criteria.
▪ Some of the UA cases would likely have been
diagnosed as non-ST elevation MI, using the
most recent criteria of MI.
▪ Treatments and risk factor profiles have partly
evolved since the study was performed.
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The Carlscrona Heart Attack Prognosis Study (CHAPS)
constitutes a patient cohort recruited before the intro-
duction of percutaneous coronary intervention (PCI),
coronary artery bypass graft (CABG) surgery and modern
antithrombotic drugs, in the management of patients
with ACS. Thus, to the best of our knowledge, this study is
unique in that MI and UA could be identiﬁed as distinct
groups within an ACS population. In a previous CHAPS
report, we demonstrated that smoking, or impaired
glucose homoeostasis, were acquired risk factors for a
severe ACS outcome.6 In the current study, the aim was to
determine if blood biomarkers of inﬂammation, for
example, high-sensitivity C reactive protein (hsCRP),
serum amyloid protein A (SAA), plasma ﬁbrinogen, and
blood cell counts and indices, are associated speciﬁcally
with either acute MI or UA in patients with ACS.
MATERIALS AND METHODS
Study design
We performed a substudy of CHAPS of patients with sus-
pected ACS. In this observational cohort substudy, we
included patients diagnosed with either MI or with UA.
Patient recruitment
The patient data have been previously described in
detail.6 In brief, in CHAPS, we recruited 5292 consecu-
tive patients admitted to the coronary intensive care unit
with acute chest pain (indicative of a possible ACS) at
Blekinge Hospital, Karlskrona, between 26 January 1992
and 25 January 1996. Of the total number of admit-
tances, 2992 were between 30 and 74 years of age at
admittance. In patients with multiple admittances, only
the ﬁrst classifying admittance was included as ‘event’
(UA or MI) in the analysis. Informed consent was
obtained from all included patients and the study com-
plies with the Declaration of Helsinki.
Outcome measures
UA or MI as diagnosed at discharge from hospital.
Patients with ACS
As previously described, a diagnosis of ACS was con-
ﬁrmed in 908 of the eligible patients 30–74 years of age
(644 men and 264 women).6 Two groups were identi-
ﬁed: (1) patients experiencing at least one acute MI
during the study (527) or (2) patients experiencing no
acute MI, but having at least one episode of UA during
the study (381). Data on environmental and lifestyle
factors, and blood samples, were collected on ﬁrst admit-
tance under the classifying diagnosis. The classifying
diagnosis was set at discharge by one of two experienced
cardiologists.
A diagnosis of acute MI was made when patients ful-
ﬁlled at least two of the following criteria: (1) a history
of chest pain of at least 15 min duration, (2) an increase
in activity of cardiac enzymes to at least twice the upper
limit of normality, or (3) characteristic ECG changes for
MI (typical sequence change of ST segment and/or of
T-waves and/or appearance of new Q-waves). These cri-
teria included both patients with ST-elevation MI
(STEMI) and those with non-STEMI (NSTEMI).
A diagnosis of UA was made when patients fulﬁlled all
of the following criteria: (1) no evidence of MI, (2)
acute chest pain of increased/modiﬁed character to any
previously experienced, during the preceding 48 h and
(3) angina pectoris diagnosed and medically treated
before admission, or alternatively, angina pectoris ascer-
tained by clinical evaluation, including a bicycle exercise
test, prior to discharge from the hospital.6
Post-infarction angina and patients with secondary
angina were not included.
Patients admitted to the coronary intensive care unit
were initially treated with aspirin and also—in case of
ongoing chest pain—nitrates and morphine. In cases of
clear diagnosis of ST elevation MI, thrombolysis with
streptokinase was given (194 of 527 patients with MI). If
the diagnosis of MI was based on cardiac markers only,
thrombolysis was not given. Acute coronary artery inter-
vention was not available at this hospital at the time of
the study.
Risk factors
Information on risk factors and medical history were
recorded at admission from patient history and/or
extracted from earlier medical ﬁles, and the diagnosis
and information were also veriﬁed at discharge from the
hospital.6 Smoking status was deﬁned as current smoker
or non-smoker. Patients who had quit smoking
>1 month prior to admission were classiﬁed as
non-smokers.
Laboratory analyses
Samples for laboratory analysis were collected at hospital
admission. A standardised protocol for obtaining data
for selected laboratory parameters was used. The proce-
dures for blood sampling and laboratory analyses fol-
lowed the routine of the Department of Clinical
Chemistry at Blekinge County Hospital and analyses
were performed in the certiﬁed hospital laboratory.
Haematological variables (blood cell count and indices)
and plasma ﬁbrinogen were analysed using routine diag-
nostic methods in fresh samples at the time of admis-
sion. Blood cell count was analysed in EDTA whole
blood by ADVIA 2120 (Siemens, Germany) and plasma
ﬁbrinogen in sodium citrate blood samples on a
Trombotrack instrument (Nycomed, Norway). Results
were extracted from the computerised hospital labora-
tory records and entered into the study database. hsCRP
and SAA were analysed in samples that had been stored
at –80°C, after thawing. Both proteins were analysed by
BN ProSpec (Siemens, Germany). These results were
entered directly into the study database. The service pro-
vided by the laboratory is subject to regular internal pre-
cision and accuracy checks, as well as external quality
2 Odeberg J, et al. BMJ Open 2016;5:e009968. doi:10.1136/bmjopen-2015-009968
Open Access
group.bmj.com on April 3, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
control measures, in accordance with the guidelines of
the Association of Clinical Chemists in Sweden. The
external control system used is EQUALIS, Sweden, and
Bio Rad UKNEQAS, England. The instruments from
Roche and Siemens are validated according to the IVD
directive. The veriﬁcation performed by the laboratory
includes intra-assay precision, correctness of measure
intervals, minimal detectable concentration, interfer-
ences, pre-analytical factors, and blood collection and
handling. All laboratory results reported from the
laboratory and included in the study are within deter-
mined intra-assay range for each assay method.
Statistical methods
STATA and IBM SPSS Statistics (V.21) were used for data
analyses. Standard methods were used for descriptive sta-
tistics. Associations were estimated by binary logistic
regression and presented by ORs with 95% CIs and p
values. Tests for trends were performed using the con-
tinuous format of the variables, and the results are pre-
sented as p values. However, for concentrations of
ﬁbrinogen, eosinophil cell count and thrombocyte
median cell volumes, the tertiles were entered as linear
variables to test for trend due to skewed distributions of
these variables. Two-way interaction terms were used to
explore the association of sex and the major risk factors
with ACS outcome.
Age was entered into the regressions as continuous
variable. Duration of chest pain from onset to blood
sampling on admission to the emergency room (ER)
was divided in ≥4 h or <4 h. Plasma levels of hsCRP were
dichotomised at 2 mg/L to categorise individuals into
high-risk and low-risk groups. This cut-off is based on
the JUPITER study, which selected individuals at high
vascular risk because of an enhanced inﬂammatory
response as indicated by hsCRP levels ≥2 mg/L.7 For
other biomarkers, to categorise into risk groups we
divided these into tertiles, using tertile 1 as reference to
obtain measures of relative risks. The tertiles were then
entered into the regression as a linear variable to test
for trend. Confounding was considered by stratiﬁcation
and by multivariate regression models forcing age, sex,
current smoking and duration ≥240 min into the same
model. Individuals with a missing variable were automat-
ically excluded in the respective analysis, thus each
multivariate analysis includes only those with full data
for every variable included. As an example, for analyses
of neutrophils, 86 patients were excluded when adjusted
for age and sex only, but 268 were excluded when also
adjusting for smoking and duration of chest pain.
Numbers remaining in the regression were accordingly
822 (90%) and 640 (70%), respectively.
RESULTS
We included 908 patients with ACS (527 MI, 381 UA).
Patient characteristics are shown in tables 1 and 2.
Outcome was similar in men and women, with no signiﬁ-
cant interaction between sex and markers of inﬂamma-
tion associated with the outcome of ACS. Results for
men and women are thus presented together. When
analysing the plasma protein inﬂammatory biomarkers,
adjusted for differences in age and sex, we found that
hsCRP>2 mg/L at hospital admission was signiﬁcantly
associated with MI over UA (OR=1.75 (1.30 to 2.34)).
MI was signiﬁcantly associated with higher ﬁbrinogen (p
for trend=0.01), and also with SAA in the highest tertile
(OR=1.66 (1.16 to 2.36), but not in the trend test (p for
trend=0.216) (table 3).
To separate an inﬂammatory response to myocardial
tissue necrosis in patients with MI from that from a pos-
sible pre-existing inﬂammation, we analysed hsCRP
Table 1 Clinical characteristics of the study population
Risk factors
Total
n=908
Men
n=644
Women
n=264
m (SD) m (SD) m (SD)
Age (years) 63.7 8.5 63.0 (8.6) 65.5 (8.0)
Serum cholesterol (mmol/L) 6.2 1.3 6.0 (1.3) 6.6 (1.4)
Plasma glucose (mmol/L) 6.9 3.5 6.8 (3.4) 7.3 (3.8)
HbA1c (%) 5.3 1.4 5.2 (1.3) 5.4 (1.7)
hsCRP (mmol/L) 9.2 21.8 9.3 (21.9) 9.0 (21.4)
Duration (min) 307 420 287 (418) 360 (421)
n (%) n (%) n (%)
Hypertension 240 (27.5) 169 (27.2) 71 (28.1)
Diabetes 142 (16.2) 92 (14.8) 50 (19.7)
Smoking (current) 191 (22.1) 148 (24.1) 43 (17.1)
Duration ≥240 min 227 (33.2) 153 (31.1) 74 (38.5)
hsCRP >2 mg/L 482 (60.5) 341 (59.3) 141 (63.5)
Data are means (m) and SD, or numbers (n) and proportions (%). Missing data age (0), serum cholesterol (n=102), plasma glucose (n=82),
HbA1c (n=108), hsCRP (n=111), duration (n=224), hypertension (n=34), diabetes (n=34), smoking (n=43).
HbA1c, glycated haemoglobin; hsCRP, high sensitivity C reactive protein.
Odeberg J, et al. BMJ Open 2016;5:e009968. doi:10.1136/bmjopen-2015-009968 3
Open Access
group.bmj.com on April 3, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
levels in relation to duration from onset of chest pain
until blood sampling. Controlling for differences in age
and sex, we found a signiﬁcant correlation of hsCRP
with duration only in those patients with MI who had
≥240 min duration since onset of symptoms (r=0.19,
p=0.033) but not in patients with MI with a shorter
duration (r=0.02, p=0.777), or in patients with UA with
≥240 min duration or shorter duration (r=−0.10,
p=0.452 and r=−0.02, p=0.779, respectively). After
including smoking and time duration since onset of
Table 3 Risk factors for an MI as outcome of ACS
(adjusted for differences in age and sex)
Risk factors OR 95% CI p Value
Male sex 1.59 1.19 to 2.13 0.002
Age (years) 1.01 1.00 to 1.02 0.178
hsCRP >2 mg/L 1.75 1.30 to 2.34 p for trend 0.037
Sex (male vs
female)
1.73 1.26 to 2.34 <0.001
Age (years) 1.00 0.98 to 1.02 0.872
Serum amyloid
Tert 1 1.0 p for trend 0.216
Tert 2 1.39 0.98 to 1.97 0.063
Tert 3 1.66 1.16 to 2.36 0.006
Fibrino
Tert 1 1.00 p for trend 0.010
Tert 2 1.26 0.90 to 1.94 0.174
Tert 3 1.62 1.12 to 2.35 0.011
Leuco
Tert 1 1.00 p for trend <0.001
Tert 2 2.78 1.97 to 3.92 <0.001
Tert 3 9.64 6.42 to 14.5 <0.001
Neutro
Tert 1 1.00 p for trend <0.001
Tert 2 2.96 2.09 to 4.20 <0.001
Tert 3 8.91 5.97 to 13.3 <0.001
Eosino
Tert 1 1.00 p for trend 0.002
Tert 2 0.65 0.45 to 0.94 0.021
Tert 3 0.56 0.39 to 0.80 0.001
Mono
Tert 1 1.00 p for trend <0.001
Tert 2 1.29 0.92 to 1.82 0.140
Tert 3 3.18 2.20 to 4.61 <0.001
T-cyt
Tert 1 1.00 p for trend 0.016
Tert 2 1.14 0.81 to 1.61 0.445
Tert 3 1.48 1.05 to 2.09 0.025
T-mcv
Tert 1 1.00 p for trend <0.001
Tert 2 0.46 0.32 to 0.65 <0.001
Tert 3 0.51 0.35 to 0.72 <0.001
Associations between risk factors and an adverse outcome of
ACS were estimated using binary logistic regression and
expressed as ORs with 95% CIs adjusting for differences in age
and sex. Plasma levels of hsCRP were dichotomised at 2 mg/L,
while other biomarkers were divided in tertiles for categorical
comparisons using tertile 1 as reference. The continuous format of
the variables was used to test for trend, however, due to skewed
distributions, the tertiles were used as a linear variable for trend
test of concentration of fibrinogen, eosinophil cell count and
T-mcv.
ACS, acute coronary syndrome; eosino, eosinophil cell count;
fibrino, fibrinogen; hsCRP, high-sensitivity C reactive protein;
leuco, leucocyte cell count; MI, myocardial infarction; mono,
monocyte cell count; neutro, neutrophil cell count; T-cyt,
thrombocyte cell count; T-mcv, thrombocyte median cell volume;
tert, tertile.
Table 2 Characteristics of plasma protein inflammatory
biomarkers categorised by tertiles in men and women
Risk factors Range
Men
n=644
Women
n=264
n (%) n (%)
Serum amyloid (mg/L)
Tert 1 0.111–3.25 209 (36.3) 57 (25.7)
Tert 2 3.26–7.44 191 (33.2) 75 (33.8)
Tert 3 7.45–1570 175 (30.4) 90 (40.5)
Fibrino (g/L)
Tert 1 1.5–3.3 233 (40.5) 77 (33.8)
Tert 2 3.4–4.0 159 (27.7) 73 (32.0)
Tert 3 4.1–10.0 183 (31.8) 78 (34.2)
Leuco (109/L)
Tert 1 2.49–7.39 196 (32.6) 85 (35.4)
Tert 2 7.4–9.8 198 (32.9) 84 (35.0)
Tert 3 9.82–80.9 207 (34.4) 71 (29.6)
Neutro (109/L)
Tert 1 0.14–4.79 191 (32.3) 84 (36.5)
Tert 2 4.81–7.04 196 (33.1) 78 (33.9)
Tert 3 7.05–20.06 205 (34.6) 68 (29.6)
Eosino (109/L)
Tert 1 0–0.06 155 (27.2) 84 (36.8)
Tert 2 0.07–0.14 186 (32.6) 77 (33.8)
Tert 3 0.15–9.12 229 (40.2) 67 (29.4)
Baso (109/L)
Tert 1 0–0.039 229 (40.7) 95 (43.0)
Tert 2 0.04–0.059 174 (30.9) 60 (27.1)
Tert 3 0.06–0.33 160 (28.4) 66 (29.9)
Lympho (109/L)
Tert 1 0.16–1.32 206 (34.8) 71 (30.9)
Tert 2 1.33–1.88 191 (32.3) 80 (34.8)
Tert 3 1.89–75.33 195 (32.9) 79 (34.3)
Mono (109/L)
Tert 1 0.04–0.4 167 (28.4) 116 (50.7)
Tert 2 0.41–0.56 212 (36.0) 59 (25.8)
Tert 3 0.57–1.60 210 (35.7) 54 (23.6)
T-cyt (109/L)
Tert 1 85–198 228 (38.1) 54 (23.6)
Tert 2 199–247 182 (30.4) 94 (39.3)
Tert 3 248–680 188 (31.4) 91 (38.1)
T-mcv (fL)
Tert 1 6.5–8.8 221 (39.4) 69 (31.4)
Tert 2 8.9–9.4 167 (29.8) 78 (35.5)
Tert 3 9.5–46.0 173 (30.8) 73 (33.2)
Missing data Serum amyloid (n=111), fibrinogen (n=106),
leucocytes (n=67), neutrophils (n=68), eosinophils (n=110),
basophils (n=124), lymphocytes (n=86), monocytes (n=90),
thrombocyte cell count (n=71), T-mcv (N=127).
Baso, basophil cell count; eosino, eosinophil cell count; fibrino,
fibrinogen; leuco, leucocyte cell count; lympho, lymphocyte cell
count; mono, monocyte cell count; neutro, neutrophil cell count;
T-cyt, thrombocyte cell count; T-mcv, thrombocyte median cell
volume; tert, tertile.
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chest pain in the model, hsCRP >2 mg/L (OR=1.40
(1.00 to 1.96)) and ﬁbrinogen (p for trend=0.031)
remain associated with MI over UA (table 4). Time dur-
ation since onset of symptoms, as such, did not reach a
statistically signiﬁcant association with MI over UA (OR
1.41 (0.98 to 2.03), table 4).
The strongest associations with MI over UA were
found when haematological variables (blood cells) were
analysed (tables 3 and 4). Of circulating inﬂammatory
blood cells, higher counts of neutrophils and mono-
cytes, and lower counts of eosinophils, were associated
with a worse outcome of ACS (table 3). These associa-
tions were not affected when adjusting for smoking and
duration of symptoms (table 4) or in trend tests where
the associations were highly signiﬁcant (p=0.003). In the
multivariate models, the outcome for smoking (highly
signiﬁcant) and duration of symptoms (borderline sig-
niﬁcant) were generally the same with all inﬂammatory
biomarkers, and is thus shown only in the ﬁrst model
with hsCRP. In contrast, lymphocyte and basophil counts
showed no association with outcome (data not shown).
Also, we found that higher thrombocyte count was asso-
ciated with MI (tables 3 and 4). Interestingly, a smaller
thrombocyte mean volume was signiﬁcantly associated
with MI when compared to UA (p for trend <0.001).
DISCUSSION
Principal findings
In the current study, we showed that levels of inﬂamma-
tory biomarkers at the time of admission are associated
with a more severe outcome in the case of ACS (ie, pre-
disposition towards MI, rather than UA). We found sig-
niﬁcant differences in blood cell proﬁles between an MI
or UA outcome, with elevated neutrophils, monocytes
and platelet counts in MI, together with a reduced
eosinophil count and lower mean platelet volume
(MPV). Plasma biomarkers for inﬂammation (hsCRP,
ﬁbrinogen and SAA) showed weaker associations. Our
results indicate that a pre-existing inﬂammation predis-
poses to a more severe outcome in ACS.8
Plasma biomarkers of inflammation and the outcome
of ACS
Previously, we used the CHAPS material to show that
genetic variations of thrombotic factors are associated
with ACS outcome9 and, furthermore, that acquired risk
factors, smoking and impaired glucose homoeostasis
together with male sex, predispose to MI over UA.6 We
have here shown that a more pronounced state of
inﬂammation conferred an increased risk towards MI,
rather than UA, in ACS. It is well established that a low-
grade inﬂammation has a pathogenic role for the pro-
gression of atherosclerotic coronary artery lesions,1
however, less known is to what extent a pre-existing
inﬂammation can inﬂuence the outcome of ACS.2 It
could be argued that elevation of inﬂammatory biomar-
kers in patients with ACS may reﬂect myocardial injury
Table 4 Risk factors for an MI as outcome of ACS
Risk factors OR 95% CI p Value
Covariates in model: sex, age, smoking, duration of
symptoms
p for trend 0.225
hsCRP >2 mg/L 1.40 1.00 to 1.96 0.049
Male sex 1.50 1.04 to 2.17 0.031
Age (years) 1.01 0.99 to 1.03 0.566
Smoking
(yes/no)
2.15 1.39 to 3.32 0.001
Duration
(≥4 vs <4 h)
1.41 0.98 to 2.03 0.061
Serum amyloid
Tert 1 1.0 p for trend 0.679
Tert 2 1.43 0.96 to 2.13 0.078
Tert 3 1.28 0.84 to 1.93 0.248
Fibrino
Tert 1 1.00 p for trend 0.031
Tert 2 1.19 0.82 to 1.74 0.349
Tert 3 1.62 1.03 to 2.55 0.039
Leuco
Tert 1 1.00 p for trend <0.001
Tert 2 2.58 1.74 to 3.83 <0.001
Tert 3 7.39 4.69 to 11.6 <0.001
Neutro
Tert 1 1.00 p for trend <0.001
Tert 2 2.58 1.74 to 3.83 <0.001
Tert 3 7.39 4.69 to 11.6 <0.001
Eosino
Tert 1 1.00 p for trend 0.003
Tert 2 0.69 0.45 to 1.07 0.069
Tert 3 0.54 0.35 to 0.81 0.003
Mono
Tert 1 1.00 p for trend <0.001
Tert 2 0.99 0.67 to 1.47 0.978
Tert 3 2.36 1.54 to 3.62 <0.001
T-cyt
Tert 1 1.00 p for trend 0.052
Tert 2 1.12 0.75 to 1.66 0.584
Tert 3 1.61 1.08 to 2.39 0.020
T-mcv
Tert 1 1.00 p for trend <0.001
Tert 2 0.41 0.27 to 0.61 <0.001
Tert 3 0.45 0.30 to 0.68 <0.001
Multivariate analysis adjusted for differences in age, sex, smoking
and duration of symptoms.
Associations between risk factors and an adverse outcome of
ACS were estimated using binary logistic regression and
expressed as ORs with 95% CIs. All models included sex, age,
smoking and duration of chest pain as covariates beside the
specified risk factor itself. Plasma levels of hsCRP ≥2 mg/L were
compared to those below, while other biomarkers were divided in
tertiles for categorical comparisons using tertile 1 as reference.
The continuous format of the variables was used to test for trend,
however, due to skewed distributions, the tertiles were used as a
linear variable for trend test of concentration of fibrinogen,
eosinophil cell count and T-mcv.
ACS, acute coronary syndrome; eosino, eosinophil cell count;
fibrino, fibrinogen; hsCRP, high-sensitivity C reactive protein;
leuco, leucocyte cell count; MI, myocardial infarction; mono,
monocyte cell count; neutro, neutrophil cell count; T-cyt,
thrombocyte cell count; T-mcv, thrombocyte median cell volume;
tert, tertile.
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rather than underlying inﬂammation. However, ﬁbrino-
gen, CRP and SAA are induced by cytokine signalling —
for example, by interleukin (IL) 1, tumour necrosis
factor and IL-61 10 11—and, due to a period of de novo
synthesis and secretion of these proteins, there is a time
lag before a rise in plasma concentration becomes
detectable during the acute phase of inﬂammation. The
average lag time of this response is 8 h10 and, further-
more, in patients with MI, there is a known latency of 6–
12 h from onset of chest pain to a rise in CRP plasma
concentrations.12 In line with this, we observed a correl-
ation between hsCRP and time only in patients with MI
where the duration between symptom onset and blood
sampling exceeded 4 h, indicating that the inﬂammatory
response to myocardial injury had a lag time of several
hours. Thus, the associations with MI over UA that we
observe in patients with duration of chest pain of <4 h
indicate that in ACS a higher pre-existing inﬂammation
predisposes to a more severe outcome. In CHAPS, we
previously found current smoking to be strongly asso-
ciated with MI, but not UA.6 We considered the possibil-
ity that these results could be explained by the known
inﬂammatory effect of smoking.13–15 However, the sig-
niﬁcant associations between MI and hsCRP and ﬁbrino-
gen, were still observed when adjusting for smoking.
Circulating inflammatory blood cells and the outcome of
ACS
The strongest associations with MI over UA were
observed when analysing circulating inﬂammatory blood
cells—independent of smoking and time duration of
symptoms to blood sampling. In contrast to plasma
protein biomarkers that require synthesis before there is
a detectable increase in levels, preformed blood cells
can be quickly mobilised into circulation by demargina-
tion from the vessel wall and egress from the bone
marrow.16 Pro-inﬂammatory cytokines stimulate neutro-
phil and monocyte production in the bone marrow.
Stress-induced release of endogenous catecholamine
and glucocorticoids can mobilise these stores shortly
after the onset of chest pain. Thus, the magnitude of
rise in cell count can reﬂect the size of the preformed
cell pool that has been increased by a pre-existing low-
grade inﬂammation.16 Thus, the difference we observed
in neutrophil and monocyte count, between MI and UA,
indicated a pre-existing inﬂammation preceding the
ACS, consistent with our observations regarding hsCRP
and ﬁbrinogen levels. In a recent population-based
cohort study, Adamsson Eryd et al17 found an association
between increased neutrophil count, and incidence of
coronary events and increased case fatality rate during
follow-up, in line with a previous meta-analysis of several
prospective population studies.18 A possible explanation
for our observation–that neutrophilia was associated with
MI when compared to UA—is a hypercoagulable or
thrombo-resistant state, as previously indicated by
reduced efﬁciency of thrombolytic therapy or primary
percutaneus coronary interventions in patients with MI
with elevated white cell count.19–21 In this context, it is
interesting that a reduced efﬁciency of primary PCIs in
patients with MI has recently been found to be asso-
ciated with an increased amount of neutrophil extracel-
lular traps (NETs) in aspirated coronary thrombi,22
adding support to the possibility of an important role
for neutrophils in the ACS thrombotic process. An asso-
ciation of an increased monocyte count and coronary
events has previously been reported from population
studies.23 24 A possible mechanism relates to the heavy
inﬁltration of monocytes/macrophages that is character-
istic of a thin ﬁbrous cap on a vulnerable plaque.25
Thus, a pre-existing monocytosis in MI, compared to
UA, might lead to greater monocytoid inﬁltration, and
predispose to a more extensive thrombotic process fol-
lowing plaque rupture.2 5 Interestingly, we found signiﬁ-
cantly lower eosinophil counts in patients with MI,
compared to those with UA, consistent with recent
reports.26 Eosinophils have been detected in aspirates
from thrombi in patients with MI,26 27 suggesting a pos-
sible role for this cell type in the progression of the
thrombotic process in ACS. Our observation could indi-
cate an active consumption of eosinophils in MI, or
reﬂect a pre-existing condition of elevated eosinophil
count and hypersensitivity inﬂammation that could pre-
dispose to UA. Indeed, Erdogan et al28 reported a signiﬁ-
cantly higher eosinophil count in patients with UA, but
not in patients with MI, when compared to controls.
Thrombocytes are key effector cells in an inﬂammatory
process29 30 and an increase of the thrombocyte count is
part of an inﬂammatory state.31 Recently, the role of
thrombocytes in vascular inﬂammation and the throm-
botic process in coronary artery disease (CAD) has been
highlighted,5 32 33 with an increased MPV reported to be
associated with acute cardiovascular events.34 35 In a sys-
tematic review and meta-analysis using pooled results
from 16 cross-sectional studies involving 2809 patients,
MPV was found to be signiﬁcantly higher in patients
with ACS than in patients with stable CAD or in healthy
individuals.34 No signiﬁcant difference in MPV was
found between patients with MI and those with UA.
Individual studies have shown both higher and lower
MPV in patients with MI over those with UA.36 37 In
ACS, thrombocytes are involved in a dynamic thrombotic
process, with consumption of preferentially more react-
ive large-sized thrombocytes.35 This is extensive and per-
manent in MI, in contrast to the recurrent episodes of
(temporary) coronary platelet aggregation and con-
sumption in UA,38 39 tending to result in a lower MPV
in MI than in UA, as in our study and the study of
Mathur et al.37 This is, however, in most studies, probably
counterbalanced by the effects on thrombocytes of a
more intense pre-existing inﬂammation in MI, leading
to a similar MPV in MI and UA.34
Strengths and limitations
The strength and novelty of CHAPS is due to the unique
nature of the patient cohort. The patients were recruited
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before the introduction of PCI, CABG and modern
antithrombotic drugs, in the standard management of
ACS. These interventions would otherwise inﬂuence the
thrombotic processes involved in ACS. The absence of
them at that time made it possible for us to identify pro-
gression to either MI or UA as distinct outcome groups
within the cohort. Furthermore, the study was based in
one centre with the same two cardiologists assessing and
categorising all patients, using consistent criteria. There
are limitations of the study that should be acknowl-
edged. Smoking was deﬁned as current smoker or non-
smoker, and thus ex-smokers (cessation >1 month ago)
were classiﬁed into the non-smoker group, however, pre-
vious studies indicate that the increased risk for cardio-
vascular events associated with smoking decreases
rapidly after smoking cessation.40 Furthermore, duration
was based on time of onset as reported by patients at
admission, which may confer a misclassiﬁcation in some
cases. Biochemical analyses of ﬁbrinogen and blood
cells were performed over a period of 4 years. The hos-
pital laboratory used standardised and certiﬁed
methods, providing consistency over time. Analyses of
hsCRP and SAA were performed using frozen samples
stored at −80°C for 15 years; quality assurance work at
the laboratory has shown that storage of samples at −80°
C did not inﬂuence determined hsCRP and SAA levels.
Furthermore, not all patients have complete data for
laboratory analyses. In the different multivariate analyses
performed, participants with missing data for any
included marker were automatically excluded, leaving
about 70% of patients in the regression for the full
model. Still, outcomes are strong and consistent with the
age and sex adjusted model, leaving 90% of patients in
the regression. Furthermore, the overall patterns show a
high internal consistency. As reﬁned criteria and more
sensitive and speciﬁc biomarkers are implemented, the
deﬁnition of MI continues to evolve. It is likely that
some of the UA cases in our study would now been diag-
nosed as NSTEMI, using recent criteria required for MI
diagnosis.8 Also, as CHAPS is a single centre study, and
treatments and risk factor proﬁles have partly developed
since the study was performed, the results would there-
fore not necessarily be generalised to a broader modern
population.
Conclusions and possible clinical implications
In conclusion, while inﬂammation is well established as
a major risk factor for development of CAD and risk of
future events, our study indicates the further role of
inﬂammation in a more severe outcome in the case of
ACS. Our data suggest that neutrophil levels can have a
prognostic value in patients with ACS, as previously pro-
posed.17 The observed differences in ACS outcome asso-
ciated with inﬂammation and blood cell proﬁles raise
several hypotheses that warrant further investigation. It is
possible that UA and MI represent different entities of
ACS that involve different pathological mechanisms.
Establishing such mechanisms at the cellular level could
lead to optimisation of pharmacological treatment for
CAD and ACS.
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